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Background: There is a strong interest in the investigation of extremely low frequency Electromagnetic Fields (EMF) in
the clinic. While evidence about anticancer effects exists, the mechanism explaining this effect is still unknown.
Methods: We investigated in vitro, and with computer simulation, the influence of a 50 Hz EMF on three cancer cell lines:
breast cancer MDA-MB-231, and colon cancer SW-480 and HCT-116. After 24 h preincubation, cells were exposed to 50
Hz extremely low frequency (ELF) radiofrequency EMF using in vitro exposure systems for 24 and 72 h. A computer
reaction-diffusion model with the net rate of cell proliferation and effect of EMF in time was developed. The fitting
procedure for estimation of the computer model parameters was implemented.
Results: Experimental results clearly showed disintegration of cells treated with a 50 Hz EMF, compared to untreated
control cells. A large percentage of treated cells resulted in increased early apoptosis after 24 h and 72 h, compared to
the controls. Computer model have shown good comparison with experimental data.
Conclusion: Using EMF at specific frequencies may represent a new approach in controlling the growth of cancer cells,
while computer modelling could be used to predict such effects and make optimisation for complex experimental
design. Further studies are required before testing this approach in humans.
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Alternating electric fields have shown a wide range of
effects on living tissues. Depending on frequencies, their
activity ranged from stimulating excitable tissues such as
nerve, muscle or heart [1,2], through stimulating bone
growth and accelerating fracture healing [3] to using it for
diathermy and radiofrequency tumour ablation [4].
Intermediate-frequency electric fields (>10 KHz to MHz)
were mostly considered as having no overt biological ef-
fect [5] and, hence, medical application, though several
non-thermal cellular effects have been observed [6-8].
The last decade also brought a number of in vitro and
in vivo studies which documented the anticancer effects of
alternating electric fields [9-11], including low-intensity
intermediate frequency (100-300 KHz) alternating electric
fields, as well as amplitude-modulated electromagnetic* Correspondence: fica@kg.ac.rs
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unless otherwise stated.fields (EMF) of somewhat lower frequencies (0.1 Hz to
114 KHz) [12]. As recently summarized [13] Zimmermann,
2013), these studies showed that anticancer effects were
achieved at specific (for the cancer cell type) modulation
frequencies and demonstrated proliferative inhibition and
mitotic spindle disruption following exposure to alternating
electric fields [10,11]. Furthermore, bridging important as-
pects of apoptosis [14,15] with extremely low frequency
(ELF) pulsed-gradient magnetic fields, Zhang et al [16]
showed that the latter can not only induce it, but may also
block the development of neovascularization required for
tumour supply. Harris et al [17] have been shown that ELF
might be capable of exacerbating an inherent or induced
genetic instability by reducing or attenuating the stringency
of the late-cycle (G2) checkpoint. Cameron et al [18]
found that mice received either gamma irradiation IR or
EMF therapy had significantly fewer lung metastatic sites
and slower tumor growth than did untreated mice. Also
they did not find harmful side effects with EMF. Initial
clinical results in various tumour entities/sites (recurrentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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breast carcinomas) were encouraging [10,12,19].
On the other side, computer models have the common
aim of predicting certain features of tumour growth in the
hope of finding new ways to combat cancer. The golden
aim of computer modelling is to create a model which
yields reproducible and accurate predictions, the effects of
different genetic, epigenetic and environmental changes,
as well as the impact of therapeutically targeting different
aspects of the tumour. In order to make a clinically rele-
vant cancer simulation tool that accurately predicts in vivo
tumour growth dynamics, shape and spread throughout
an organ, computational models must consider the loca-
tion of a tumour within the organ, and the physical con-
straints placed on growth by that organ. Treatment plans
based on the use of such computer modelling and simula-
tion processes will require rigorous validation studies and
regulatory approvals before integration into the clinical
practice [20].
Based on these premises, we investigated the influence
of EMF at specific frequencies on three cell lines in an
in vitro setting.Methods
Experimental design for electromagnetic field
The experiment is performed using the two coils with
11300 copper windings each. The coils are appointed in
vertical position and connected in parallel to the alternate
current source as it has been shown in the Figure 1A,B.
According to right hand screw rule the achieved connec-
tion enable superposition of magnetic field from both coils
and maximum intensity in the center between coils.
The VC2002 function signal generator is used with out-
put voltage of 9.1 V peak to peak values and frequency of
50 Hz and current amplifier up to 1A. The applied field is
with frequency of 50 Hz with RMS value of 10 mT. Envir-
onmental background magnetic field is several μT order
so it can be neglected.Cell preparation and culturing
The breast cancer cell line, MDA-MB-231, and colon can-
cer cell lines, SW480 and HCT-116, were obtained from
the American Tissue Culture Collection (Manassas, VA,
USA). Cells were propagated and maintained in Dulbecco’s
Modified Eagle Medium (DMEM), (Gibco, USA), supple-
mented with 10% foetal bovine serum (PAA) and antibi-
otics (100 IU/mL penicillin and 100 μg/mL streptomycin).
Cells were grown in 75 cm2 culture flasks containing 15 ml
DMEM. After a few passages cells were seeded in a 96-well
plate (104 cells per well) and cultured in a humidified at-
mosphere of 5% CO2 at 37°C. All studies used cells at 70 to
80% confluence.Cell viability assay (MTT assay)
Cell viability was determined by MTTassay [21]. After 24 h
incubation cells were exposed to 50 Hz EMF using in vitro
exposure systems, for 24 h and 72 h [21-23]. Untreated
cells served as the control. At the end of the period of ex-
posure, MTT (final concentration 5 mg/ml in PBS) was
added to each well, and the multiwell plate incubated at
37°C in 5% CO2 for 2 h. The coloured crystals of produced
formazan were dissolved in dimethyl sulfoxide (DMSO)
(Sigma, USA). The absorbance was measured at 550 nm.
Cell proliferation was calculated as the ratio of the absorb-
ance of the treated group, divided by the absorbance of
the control group, multiplied by 100, to give percentage of
proliferation [21].
Fluorescence microscopic analysis of cell death with
acridine orange/ethidium bromide (AO/EB) double staining
For analysis of cell death, we used fluorescent assays
AO/EB double staining [22]. AO is taken up by both viable
and nonviable cells and emits green fluorescence when it
bonds with double stranded nucleic acid (DNA), or red
fluorescence if bound to single stranded nucleic acid
(RNA). Ethidium Bromide is taken up only by nonviable
cells and emits red fluorescence by intercalation with DNA.
We distinguished four types of cells according to the fluor-
escence emission and the morphological aspect of chroma-
tin condensation in the stained nuclei. Viable cells have
uniform bright green nuclei with an organized structure.
Early apoptotic cells have green nuclei, but perinuclear
chromatin condensation is visible as bright green patches
or fragments. Late apoptotic cells have orange to red nuclei
with condensed or fragmented chromatin. Necrotic cells
have uniformly orange to red nuclei with condensed struc-
ture. 20 μl of dye mixture (10 μg/ml AO and 10 μg/ml EB
in distilled water) was mixed with 100 μl cell suspension
(10 000 cells/ml) in a 96-well plate. After incubation times
(24 h and 72 h) the suspension was immediately examined
and viewed using a Nikon inverted fluorescent microscope
(Ti-Eclipse) at 400x magnification. Untreated cells were
used as controls.
Statistical analysis
A minimum of 300 cells was counted in each sample.
Results were expressed as the Mean ± SE for three inde-
pendent determinations. Biological activity was the result
of one individual experiment, performed in triplicate.
Correlation between variables was investigated using a
SPSS (Chicago, IL) statistical software package (SPSS for
Windows, ver. 17, 2008).
Numerical modelling of effect of electromagnetic field on
cancer cells
To develop a mathematical model capable of accurately
predicting the influence of EMF on cancer cells, we used
Figure 1 (A) Scheme of experiment, (B) Experimental setup.
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for brain tumours, but also to model the behaviour of any
untreated tumour [25]. Extensions of this model included
the effects of radiation therapy [25], resection [26] and
chemotherapy [27]. Here, the fundamental model was ex-
tended to take into account the effect of EMF.






þ ρc−F tð Þc ð1Þ
where c = c(x, t) is the concentration of tumour cells, D
is the spatially constant diffusion coefficient (defining
cell migration), ρ is the net rate of cell proliferation and
F(t) represents the effect of EMF at time t.
The initial and boundary conditions are set such that
at t = 0 the cell concentration is set to c0 and the zero
flux is prescribed on the boundary of the observed do-
main - n ⋅ ∇c = 0. In-house developed software was used
for imaging analysis of experimental results (images of
cells in 96-well plate obtained during the experiment).
All the areas of cells visible on experimental images are
summed and the cumulative single cell with the same
area created, as shown in Figure 2. The initial cell con-
centration is determined using this software and images
from the beginning of the experiment. The same proced-
ure was used to evaluate the percentage of cells over thewhole observed domain after 24h and 72h of cell exposure
to EMF. These percentages were later used for parameter
estimation.
Since the effect of EMF is represented by an unknown
function, it was necessary to estimate the function itself
and the parameters. Examining the experimental results,
it was concluded that the following logarithmic function
would best model the effect of EMF:
F tð Þ ¼ a ln tð Þ þ b ð2Þ
where parameters a and b have to be estimated.
Parameters describing the diffusion and proliferation of
cancer cells are different for different types of tumours
and should be estimated accordingly. Hence, the following
parameters need to be estimated using the experimental
results - D, ρ, a and b. The equation (1) was solved
numerically using the finite element method [28]. The
in-house developed software for time-dependent two-
dimensional analysis was used for this purpose. The
incremental-iterative form of equation (1) for time step Δt





⋅Δc ið Þ ¼ tþΔtFði1Þc ð3Þ
The index “t +Δt” denotes that the quantities in question
are calculated at the end of a time step. The matrix Mc is
Figure 2 The procedure of creation of a single cumulative cell
for the numerical model from experimental images.
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included the effects of electromagnetic field) and Fc is the
forcing vector, that takes into account the boundary condi-
tions. The space step for the simulation is 1 μm and the
time step in the simulation is 1 min.
Fitting procedure
Its aim is to determine diffusion coefficient D, proliferation
rate ρ and parameters a and b from the logarithmic
function in equation (2). To minimize differences between
computer simulations and experiments, we used a hybrid
genetic algorithm which combines the power of the gen-
etic algorithm with the speed of the local optimizer. We
used a standard genetic algorithm [29] to find the area of
the global minimum, then the Nelder-Mead simplex
optimization algorithm [30] to take over and find the
value of the global minimum.
The best fit minimizes the sum of squared residuals,
where residuals represent the differences between experi-
mental and simulation cell area percentages after 24 and72 hours. We have three experiments with, and three
without, the effect of EMF, thus six different functions to
minimize, and six sets of parameters to determine. These
functions are:
SE ¼ Ae24h−As24h
 2 þ Ae72h−As72h 2 ð4Þ
where Ae24h and A
e
72h are experimental cell area percent-
ages after 24 and 72 hours. As24h and A
s
72h are cell area




The difference between the survival of EMF-exposed cells
and control cells, as well as the difference between different
cell types was observed. The percentages of cell viability
after exposure to EMF are given in Figure 3A and B, re-
spectively. The EMF inhibited cell growth in each of the
three investigated cell lines, being very similar between the
two colon cancer cell lines (88.53% viable SW480 cells after
24 h, and 94.19% after 72 h, and 98.28% viable HCT-116
cells after 24 h, and 97.20% after 72 h). However, the breast
cancer cell line MDA-MB-231 was more sensitive to EMF
after both investigated exposure times (inhibition > 50% of
MDA-MB-231 cell growth). Only inhibition of the cell
growth of treated HCT-116 was not statistically significant
in comparison to control HCT-116 cells. Extending the
exposure time did not enhance EMF effects. Importantly,
higher cell viabilities were observed after 72 h, indicating
that EMF had antiproliferative activity which decreased
with time.
The results obtained with AO/EB double staining
To determine the type of cell death induced by EMF in
MDA-MB-231, HCT-116 and SW480 cells, the AO/EB
method was used. Figure 4(A) and (C) show the intact
viable cells (V) and Figure 4(B) and (D) show typical
morphological changes after cell exposure to an EM field.
After cell exposure to an EMF, cells showed changes in cel-
lular morphology, including reduction in cell volume, chro-
matin condensation, membrane blebbing, and fragmented
nuclei. The AO/EB method was used for differentiation
and quantification of viable, apoptotic and necrotic cells.
Tables 1 and 2 summarize the results obtained with AO/EB
double staining. The percentages of viable, apoptotic and
necrotic cells were noted for two incubation periods. Com-
pared with spontaneous apoptosis observed in control cells
(Tables 1 and 2), exposure to an EMF resulted in a reduc-
tion in the number of viable cells, increased percentages of
apoptotic cells in different percentages depending of cell
line. Generally, EMF had proapoptotic activity. EMF did
not cause necrosis in the investigated colon cancer cell lines
Figure 3 Effects of 50 Hz EMF on the cancel cell after 24h and 72h of exposure. (A) After 24h of exposure. (B) After 72h of exposure. The
histogram of effects of 50 Hz EMF on human breast cancer cell line MDA-MB-231 and colon cancer cell lines HCT-116 and SW-480. The antiproliferative
effect was measured by MTT assay after 24 h of exposure. All values are mean ± SEM, n = 3, *p < 0.05 as compared with control (100%).
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MDA-MB-231 cells (9.68%).
Results of the fitting procedure
Results of the fitting procedure from numerical simula-
tion are given in Tables 3 and 4, respectively (coefficients
a and b for the influence of EMF do not exist for control
cases in Table 3). The estimated diffusion coefficient is
very small, which is in accordance with the fact that cells
are practically not migrating throughout the domain.
Even with an approximation of a single cumulative cell
model, computer results seem very promising. Figure 5
shows the diagram of variation of cell percentages over
the whole domain with respect to time. The red line rep-
resents the control cancer cell line, where no EMF was
applied. The blue line represents the cancer cell line
with EMF acting on cells. The black line represents the
effect of EMF, which was modelled using the logarithmic
function described in equation (2). The results obtained
are shown for three different states in time above the
diagram in Figure 5. These specific moments in time were
chosen because the state of cells during experiments was
pictured at these moments and those images are also
shown in Figure 5.In an attempt to explore new avenues of cancer research,
we focused on a local treatment with EMF. In contrast to
most anticancer agents, EMFs are not associated with any
meaningful systemic toxicity [29-34]. Furthermore, it was
recently shown that EMF may be used clinically, not only
as an antiproliferation agent, but also as an effective adju-
vant to currently used chemotherapeutic agents.
The aim of this study was to investigate the influence of
EMF on three cancer cell lines. The analysis was per-
formed in vitro and by computer simulation. After 24 h
incubation cells were exposed to 50 Hz radiofrequency
EMF using in vitro exposure systems for 24 h and 72 h.
We developed a specific reaction-diffusion model with the
net rate of cell proliferation and effect of EMF in time.
Also, the fitting procedure for estimation of the computer
model parameters was applied.
The disintegration of cells treated by EMF of 50 Hz
frequency compared with untreated control cells was
clearly shown. EMF had antiproliferative and proapoptotic
activity in varying degrees, depending on the cell lines and
time of exposure. The effect can be explained according to
two proposed mechanisms [28]: during cytokinesis and
during cell division when it interferes with the micro-
tubule spindle polymerization processes. Thus, EMF
Figure 4 Untreated and treated cancer cells with 50 Hz EMF after 24 and 72 h. (A) Untreated cells were observed as control. (B) Treated cells
of 50 Hz EMF after 24 h. (C) Untreated cells were observed as control. (D) Treated cells of 50 Hz EMF after 72 h. AO/EB staining of MDA-MB-231, SW-480
and HCT-116 to detect the type of cell death induced by 50 Hz EMF. Magnification on fluorescent microscope was 400×. VC-Viable cells; EA-Early apoptotic
cells; LA-Late apoptotic cells; NC-Necrotic cells.
Table 1 Effect of 50 Hz EMF on cell death of human breast cancer cell line MDA-MB-231 and colon cancer cell lines SW-480
and HCT-116 stained with AO/EB and analyzed under a fluorescence microscope after 24 h
Cell lines VC EA LA NC
Control MDA-231 97,92 ± 0,24 2,07 ± 0,46 0 0
50 Hz EMF MDA-231 87,577 ± 0,33* 2,705 ± 0,45 0,278 ± 0,27 9,68 ± 0,82
Control SW480 95,07 ± 0,25 4,92 ± 0,25 0 0
50 Hz EMF SW480 95,428 ± 0,32 3,266 ± 0,60 0,130 ± 0,13 1,168 ± 0,43
Control HCT-116 93,75 ± 1,91 6,25 ± 1,91 0 0
50 Hz EMF HCT-116 86,948 ± 1,01* 12,63 ± 1,59* 0,235 ± 0,23 0,175 ± 0,17
n = 3, *p < 0.05 as compared with control.
VC-viable cells; EA- early apoptosis; LA-late apoptosis; NC-necrotic cells.
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Table 2 Effect of 50 Hz EMF on cell death of human breast cancer cell line MDA-MB-231 and colon cancer cell lines SW-480
and HCT-116 stained with AO/EB and analyzed under a fluorescence microscope after 72 h
Cell lines VC EA LA NC
Control MDA-231 95,74 ± 0,60 4,25 ± 0,60 0 0
50 Hz EMF MDA-231 94,05 ± 1,39* 5,63 ± 1,39* 0 0
Control SW-480 94,05 ± 0,07 5,95 ± 0,07 0 0
50 Hz EMF SW-480 80,459 ± 1,83* 18,99 ± 1,29* 0,46 ± 0,175 0,075 ± 0,075
Control HCT-116 96,38 ± 3,31 3,62 ± 0.23 0 0
50 Hz EMF HCT-116 94,16 ± 1,19* 5,82 ± 1,19* 0 0
n = 3, *p < 0.05 as compared with control.
VC-viable cells; EA- early apoptosis; LA-late apoptosis; NC-necrotic cells.
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sults in cell death.
These results add to the existing knowledge in this field.
Following encouraging in vitro and in vivo results [9],
Kirson et al [10] used alternating EMFs in 10 patients with
recurrent glioblastoma multiforme. The median time to
disease progression was 26.1 weeks (range, 3-124 weeks)
and the progression-free survival time at 6 months was
50%. The median overall survival time (MST) was 62.2
weeks at the time of the report (range, 20.3-124 weeks),
seemingly an improvement which was more than double
when compared to historic controls. No serious adverse
events (SAE) were observed, while 9 out of 10 patients
experienced mild to moderate (grade 1 and 2, respectively)
contact dermatitis beneath the electrode gel, all success-
fully treated with topical steroid creams and periodic elec-
trode relocation.
In an interesting approach, Barbault et al [12] tried to
identify tumour-specific frequencies in patients with ad-
vanced cancer using a non-invasive biofeedback method
to identify such tumour-specific frequencies. In 163 ex-
amined patients, a total of 1524 frequencies ranging
from 0.1 Hz to 114 KHz were identified. Most frequen-
cies (57-92%) were specific for a single tumour type.
Self-administered treatment, three times a day, was of-
fered to 28 patients (26 treated in Switzerland and 2 in
Brazil). Thirteen patients were evaluated for response.Table 3 Fitted values of D, ρ, a and b
Cell lines D ρ a b
HCT 0.00769 0.09412 0.0069 0.0670
MDA 0.00149 0.08876 0.0067 0.0652
SW 0.00014 0.11498 0.0100 0.0863
Control HCT 0.01665 0.00914
Control MDA 0.00633 0.00785
Control SW 0.00606 0.00421
D = diffusion coefficient; ρ = proliferation rate; a and b = parameters from the
logarithmic function in eq. (2).Both patients with hormone-refractory metastatic breast
cancer achieved either a complete response (lasting 11
months), or a partial response (lasting 13.5 months).
Four patients had stable disease (SD) (range 4.0 to >34.1
months), while only one patient experienced grade 1
fatigue.
The largest study so far has been published by Costa et al
[19] with 41 patients having advanced hepatocellular
carcinoma treated with low levels of EMF modulated at
specific frequencies (27.12 MHz). Three-daily outpatient
treatments were administered until disease progression or
death. The majority of these patients had either failed
standard treatment options or had severely impaired liver
function that limited their ability to tolerate any form of
systemic or intrahepatic therapy. Fourteen (34.1%) pa-
tients had SD for > 6 months. Median progression-free
survival was 4.4 months and MST was 6.7 months, with
no grade 2-5 treatment-related toxicities observed. This
data seems comparable to recent data from other therap-
ies in this setting [14].
Having a long lasting interest in computer modelling,
we have developed a model that intends to simulate the
influence of EMF on cancer cells. The images of experi-
mental setup were used to create a cumulative single cell
for computer simulation. In our approximation, we
achieved very good comparison with the in vitro results.
However, any computer model used in the clinic must
precisely predict tumour size and shape. Future com-
puter models, too, have to predict the changes induced
in the host by the growing tumour, and the impact that
one or multiple treatment strategies could have on halt-
ing tumour progression. Also probably patient specific
EMF frequency could be optimised through computer
simulation. We choose extremely low frequency 50 Hz
from literature [13,35] but further research should go in
the direction of investigation more frequencies. In
addition, we would like to emphasize that the evidence
from (only) two different cancer cell lines may well not
be enough to infer to conclusions about the effect of
EMF in cancer. We plan to use current study findings to
Figure 5 Comparison of experimental and numerical results. The experimental images, obtained numerical results, and diagram of cell percentage
variation, with respect to time.
Table 4 Comparison between experimental and computer simulation results











HCT 0.36301 0.49453 0.39287 0.38828 0.01731
MDA 0.17442 0.22891 0.18731 0.18828 0.00297
SW 0.14670 0.15703 0.12372 0.12266 0.00010
Control HCT 0.38432 0.37578 0.37731 0.37812 7.3x10−5
Control MDA 0.15823 0.16641 0.15470 0.15391 6.7x10−5
Control SW 0.29761 0.30078 0.27990 0.27891 0.00001
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pathways: one, by considering a certain class of cancers,
modulated by the same genes, and two, by using several
cell lines, belonging to the same cancer. In the first case,
one could prove that EMF may be useful for “similar
cancers”, while in the second case one could prove that
a specific cancer could be affected by EMF. Based on
findings, further in vivo studies would be needed as to
bridge the gap towards initial clinical use, by, hopefully,
identifying those cancers which may be good target
groups in this setting.
Results in the current study had been obtained with the
use of EMF alone. It is, however, interesting to observe that
additional anticancer treatment, namely chemotherapy, can
also be added in order to improve treatment results in
clinic due to possible synergistic effects. EMF in combin-
ation with various chemotherapeutic and targeted agents
demonstrated no increase in side effects clinically, while
similar findings were reported in vitro [12,36]. Other
treatment modalities such as magnetic nano-particles,
ultrasound, and/or radiotherapy [37,38]. Of particular
importance is the finding of the recent phase III study [39]
in recurrent glioblastoma multiforme which showed effi-
cacy similar to the standard chemotherapy regimen but
with fewer adverse effects [39]. The use of similar devices
are eagerly awaited to be tested in a number of tumor sites.Conclusion
Findings of the current study seem to reconfirm potential
application of EMF in oncology. Computer simulation
tools also uncover a new avenue to optimize control of
tumour growth and may have broad implications for the
treatment of cancer. These results call for additional inves-
tigations before being tested in a phase I-II clinical trial.
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